bioAffinity Technologies (NASDAQ:BIAF) Releases Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) issued its earnings results on Friday. The company reported ($0.64) earnings per share (EPS) for the quarter, FiscalAI reports. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.The company had revenue of $1.51 million during the quarter.

bioAffinity Technologies Stock Performance

bioAffinity Technologies stock traded down $0.02 during mid-day trading on Friday, reaching $0.51. 504,541 shares of the company were exchanged, compared to its average volume of 3,803,363. The firm’s 50-day simple moving average is $0.93 and its two-hundred day simple moving average is $1.64. bioAffinity Technologies has a twelve month low of $0.51 and a twelve month high of $13.50. The firm has a market cap of $2.42 million, a PE ratio of -0.04 and a beta of -1.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.34 and a current ratio of 1.36.

Analysts Set New Price Targets

Several research firms recently issued reports on BIAF. Wall Street Zen cut shares of bioAffinity Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, August 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On bioAffinity Technologies

Several institutional investors have recently bought and sold shares of the company. J. Safra Sarasin Holding AG purchased a new position in bioAffinity Technologies during the 1st quarter worth $164,000. Geode Capital Management LLC purchased a new stake in shares of bioAffinity Technologies in the fourth quarter valued at about $36,000. Finally, Scientech Research LLC acquired a new position in shares of bioAffinity Technologies during the third quarter worth about $49,000. 1.64% of the stock is owned by institutional investors and hedge funds.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.